sirt7 shrna Search Results


adeno associated virus aav  (Vector Biolabs)
94
Vector Biolabs adeno associated virus aav
Adeno Associated Virus Aav, supplied by Vector Biolabs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adeno associated virus aav/product/Vector Biolabs
Average 94 stars, based on 1 article reviews
adeno associated virus aav - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
shrna against sirt7  (Santa Cruz Biotechnology)
91
Santa Cruz Biotechnology shrna against sirt7
Oocytes were injected with KCC4 WT with and without <t>SIRT7</t> for 48 h and then incubated with vehicle (V) or NAM for 4 h. KCC4 protein levels and acetylated proteins were analyzed by SDS–PAGE/immunoblotting using an anti‐acetyl lysine antibody.
Shrna Against Sirt7, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/shrna against sirt7/product/Santa Cruz Biotechnology
Average 91 stars, based on 1 article reviews
shrna against sirt7 - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier
sirt7 shrna h lentivirus  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology sirt7 shrna h lentivirus
<t>SIRT7</t> is increased in human lung cancer tissues and cell lines. (A-C) IHC analysis of SIRT7 in human lung cancer TMA. (A) The representative IHC images of Case 5 (tumor tissue IHC score: -), Case 37 (tumor tissue IHC score: +), Case 69 (tumor tissue IHC score: ++) and Case 6 (tumor tissue IHC score: +++). (B) The number of IHC scoring -, +, ++ or +++ cases in 102 paired lung cancer tumor/adjacent non-tumor tissues. P<0.001, Mann-Whitney U test. (C) The percentage of high/low SIRT7 expression in lung cancer tumor/adjacent non-tumor tissues. *P<0.05, Pearson's χ 2 test. T, tumor tissue; N, adjacent non-tumor tissue. (D) The relative level of SIRT7 mRNA in human NSCLC cells (HBEpiC served as a control) analyzed by RT-qPCR. (E and F) Analysis of SIRT7 protein in NSCLC cells by western blotting. (E) The representative western blot images. (F) The relative level of SIRT7 protein in NSCLC cells (HBEpiC served as a control). *P<0.05, one-way repeated measures ANOVA with LSD post hoc multiple comparisons, n=6 per group. SIRT7, sirtuin 7; IHC, immunohistochemistry; TMS, tissue microarray; NSCLC, non-small cell lung cancer; ANOVA, analysis of variance; LSD, least significant difference.
Sirt7 Shrna H Lentivirus, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sirt7 shrna h lentivirus/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
sirt7 shrna h lentivirus - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
sirt7 human shrna plasmid kit  (OriGene)
90
OriGene sirt7 human shrna plasmid kit
<t>SIRT7</t> is increased in human lung cancer tissues and cell lines. (A-C) IHC analysis of SIRT7 in human lung cancer TMA. (A) The representative IHC images of Case 5 (tumor tissue IHC score: -), Case 37 (tumor tissue IHC score: +), Case 69 (tumor tissue IHC score: ++) and Case 6 (tumor tissue IHC score: +++). (B) The number of IHC scoring -, +, ++ or +++ cases in 102 paired lung cancer tumor/adjacent non-tumor tissues. P<0.001, Mann-Whitney U test. (C) The percentage of high/low SIRT7 expression in lung cancer tumor/adjacent non-tumor tissues. *P<0.05, Pearson's χ 2 test. T, tumor tissue; N, adjacent non-tumor tissue. (D) The relative level of SIRT7 mRNA in human NSCLC cells (HBEpiC served as a control) analyzed by RT-qPCR. (E and F) Analysis of SIRT7 protein in NSCLC cells by western blotting. (E) The representative western blot images. (F) The relative level of SIRT7 protein in NSCLC cells (HBEpiC served as a control). *P<0.05, one-way repeated measures ANOVA with LSD post hoc multiple comparisons, n=6 per group. SIRT7, sirtuin 7; IHC, immunohistochemistry; TMS, tissue microarray; NSCLC, non-small cell lung cancer; ANOVA, analysis of variance; LSD, least significant difference.
Sirt7 Human Shrna Plasmid Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sirt7 human shrna plasmid kit/product/OriGene
Average 90 stars, based on 1 article reviews
sirt7 human shrna plasmid kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Oocytes were injected with KCC4 WT with and without SIRT7 for 48 h and then incubated with vehicle (V) or NAM for 4 h. KCC4 protein levels and acetylated proteins were analyzed by SDS–PAGE/immunoblotting using an anti‐acetyl lysine antibody.

Journal: EMBO Reports

Article Title: SIRT7 modulates the stability and activity of the renal K‐Cl cotransporter KCC4 through deacetylation

doi: 10.15252/embr.202050766

Figure Lengend Snippet: Oocytes were injected with KCC4 WT with and without SIRT7 for 48 h and then incubated with vehicle (V) or NAM for 4 h. KCC4 protein levels and acetylated proteins were analyzed by SDS–PAGE/immunoblotting using an anti‐acetyl lysine antibody.

Article Snippet: For stability assay, HEK293 cells were transfected with 50 ng of KCC4, 100 ng of SIRT7, and 200 ng of a scramble shRNA or shRNA against SIRT7 (sc‐63031‐sh, Santa Cruz Biotechnology).

Techniques: Injection, Incubation, SDS Page, Western Blot

Blood gasometry and urine pH and electrolytes of mice exposed to 280 mM NH4Cl solution for 8 days.

Journal: EMBO Reports

Article Title: SIRT7 modulates the stability and activity of the renal K‐Cl cotransporter KCC4 through deacetylation

doi: 10.15252/embr.202050766

Figure Lengend Snippet: Blood gasometry and urine pH and electrolytes of mice exposed to 280 mM NH4Cl solution for 8 days.

Article Snippet: For stability assay, HEK293 cells were transfected with 50 ng of KCC4, 100 ng of SIRT7, and 200 ng of a scramble shRNA or shRNA against SIRT7 (sc‐63031‐sh, Santa Cruz Biotechnology).

Techniques: Control

SIRT7 is increased in human lung cancer tissues and cell lines. (A-C) IHC analysis of SIRT7 in human lung cancer TMA. (A) The representative IHC images of Case 5 (tumor tissue IHC score: -), Case 37 (tumor tissue IHC score: +), Case 69 (tumor tissue IHC score: ++) and Case 6 (tumor tissue IHC score: +++). (B) The number of IHC scoring -, +, ++ or +++ cases in 102 paired lung cancer tumor/adjacent non-tumor tissues. P<0.001, Mann-Whitney U test. (C) The percentage of high/low SIRT7 expression in lung cancer tumor/adjacent non-tumor tissues. *P<0.05, Pearson's χ 2 test. T, tumor tissue; N, adjacent non-tumor tissue. (D) The relative level of SIRT7 mRNA in human NSCLC cells (HBEpiC served as a control) analyzed by RT-qPCR. (E and F) Analysis of SIRT7 protein in NSCLC cells by western blotting. (E) The representative western blot images. (F) The relative level of SIRT7 protein in NSCLC cells (HBEpiC served as a control). *P<0.05, one-way repeated measures ANOVA with LSD post hoc multiple comparisons, n=6 per group. SIRT7, sirtuin 7; IHC, immunohistochemistry; TMS, tissue microarray; NSCLC, non-small cell lung cancer; ANOVA, analysis of variance; LSD, least significant difference.

Journal: Oncology Reports

Article Title: Sirtuin 7 promotes non-small cell lung cancer progression by facilitating G1/S phase and epithelial-mesenchymal transition and activating AKT and ERK1/2 signaling

doi: 10.3892/or.2020.7672

Figure Lengend Snippet: SIRT7 is increased in human lung cancer tissues and cell lines. (A-C) IHC analysis of SIRT7 in human lung cancer TMA. (A) The representative IHC images of Case 5 (tumor tissue IHC score: -), Case 37 (tumor tissue IHC score: +), Case 69 (tumor tissue IHC score: ++) and Case 6 (tumor tissue IHC score: +++). (B) The number of IHC scoring -, +, ++ or +++ cases in 102 paired lung cancer tumor/adjacent non-tumor tissues. P<0.001, Mann-Whitney U test. (C) The percentage of high/low SIRT7 expression in lung cancer tumor/adjacent non-tumor tissues. *P<0.05, Pearson's χ 2 test. T, tumor tissue; N, adjacent non-tumor tissue. (D) The relative level of SIRT7 mRNA in human NSCLC cells (HBEpiC served as a control) analyzed by RT-qPCR. (E and F) Analysis of SIRT7 protein in NSCLC cells by western blotting. (E) The representative western blot images. (F) The relative level of SIRT7 protein in NSCLC cells (HBEpiC served as a control). *P<0.05, one-way repeated measures ANOVA with LSD post hoc multiple comparisons, n=6 per group. SIRT7, sirtuin 7; IHC, immunohistochemistry; TMS, tissue microarray; NSCLC, non-small cell lung cancer; ANOVA, analysis of variance; LSD, least significant difference.

Article Snippet: The pGEM/SIRT7 cloning plasmid carrying human SIRT7 coding sequence (CDS) (BC017305) was supplied by Sino Biological, Inc. Plasmids including pLenti6.3/IRES/GFP lentiviral plasmid-expressing blasticidin S deaminase and green fluorescent protein (GFP) as well as pLP1, pLP2 and VSVG lentiviral packing plasmids were supplied by Novobio Scientific, Inc. Lentiviruses including control shRNA lentivirus (LV-shcontrol) and SIRT7 shRNA (h) lentivirus (LV-shSIRT7) containing puromycin resistance gene were supplied by Santa Cruz Biotechnology, Inc.

Techniques: MANN-WHITNEY, Expressing, Control, Quantitative RT-PCR, Western Blot, Immunohistochemistry, Microarray

The association of SIRT7 expression with lung cancer clinicopathological features.

Journal: Oncology Reports

Article Title: Sirtuin 7 promotes non-small cell lung cancer progression by facilitating G1/S phase and epithelial-mesenchymal transition and activating AKT and ERK1/2 signaling

doi: 10.3892/or.2020.7672

Figure Lengend Snippet: The association of SIRT7 expression with lung cancer clinicopathological features.

Article Snippet: The pGEM/SIRT7 cloning plasmid carrying human SIRT7 coding sequence (CDS) (BC017305) was supplied by Sino Biological, Inc. Plasmids including pLenti6.3/IRES/GFP lentiviral plasmid-expressing blasticidin S deaminase and green fluorescent protein (GFP) as well as pLP1, pLP2 and VSVG lentiviral packing plasmids were supplied by Novobio Scientific, Inc. Lentiviruses including control shRNA lentivirus (LV-shcontrol) and SIRT7 shRNA (h) lentivirus (LV-shSIRT7) containing puromycin resistance gene were supplied by Santa Cruz Biotechnology, Inc.

Techniques: Expressing

Overexpression/knockdown of SIRT7 in human NSCLC cells. (A) GFP analysis by fluorescence microscopy. (B) GFP analysis by flow cytometry. (C) SIRT7 overexpression or knockdown efficiency detected by RT-qPCR. (D) SIRT7 overexpression or knockdown efficiency detected by western blotting. The representative western blot images are presented in the upper panel. The relative level of SIRT7 protein in A549-SIRT7 (A549-mock served as a control) and H292-shSIRT7 (H292-shcontrol served as a control) NSCLC cells are presented in the lower panel. *P<0.05, Student's t -test, n=6 per group. SIRT7, sirtuin 7; NSCLC, non-small cell lung cancer; GFP, green fluorescent protein; reverse transcription-quantitative PCR.

Journal: Oncology Reports

Article Title: Sirtuin 7 promotes non-small cell lung cancer progression by facilitating G1/S phase and epithelial-mesenchymal transition and activating AKT and ERK1/2 signaling

doi: 10.3892/or.2020.7672

Figure Lengend Snippet: Overexpression/knockdown of SIRT7 in human NSCLC cells. (A) GFP analysis by fluorescence microscopy. (B) GFP analysis by flow cytometry. (C) SIRT7 overexpression or knockdown efficiency detected by RT-qPCR. (D) SIRT7 overexpression or knockdown efficiency detected by western blotting. The representative western blot images are presented in the upper panel. The relative level of SIRT7 protein in A549-SIRT7 (A549-mock served as a control) and H292-shSIRT7 (H292-shcontrol served as a control) NSCLC cells are presented in the lower panel. *P<0.05, Student's t -test, n=6 per group. SIRT7, sirtuin 7; NSCLC, non-small cell lung cancer; GFP, green fluorescent protein; reverse transcription-quantitative PCR.

Article Snippet: The pGEM/SIRT7 cloning plasmid carrying human SIRT7 coding sequence (CDS) (BC017305) was supplied by Sino Biological, Inc. Plasmids including pLenti6.3/IRES/GFP lentiviral plasmid-expressing blasticidin S deaminase and green fluorescent protein (GFP) as well as pLP1, pLP2 and VSVG lentiviral packing plasmids were supplied by Novobio Scientific, Inc. Lentiviruses including control shRNA lentivirus (LV-shcontrol) and SIRT7 shRNA (h) lentivirus (LV-shSIRT7) containing puromycin resistance gene were supplied by Santa Cruz Biotechnology, Inc.

Techniques: Over Expression, Knockdown, Fluorescence, Microscopy, Flow Cytometry, Quantitative RT-PCR, Western Blot, Control, Reverse Transcription, Real-time Polymerase Chain Reaction

SIRT7 promotes growth and G1 to S-phase transition of human NSCLC cells. (A) CCK-8 analysis of NSCLC cell proliferation/growth. *P<0.05, two-way repeated measures ANOVA with LSD post hoc multiple comparisons, n=6 per group. (B and C) Colony formation assay. (B) The representative images. (C) The relative clonogenic ability of A549-SIRT7 (A549-mock served as a control) and H292-shSIRT7 (H292-shcontrol served as a control) NSCLC cells. *P<0.05, Student t -test, n=6 per group. (D-F) Tumor subcutaneous xenograft mouse model. (D) Tumor volume. *P<0.05, two-way repeated measures ANOVA with LSD post hoc multiple comparisons, n=6 per group. (E) The xenograft tumor images. (F) Tumor weight. *P<0.05, Student's t -test, n=6 per group. (G and H) Cell cycle analysis by flow cytometry. (G) The representative images. (H) The percentage of each cell cycle phase. *P<0.05, Student's t -test, n=6 per group. SIRT7, sirtuin 7; NSCLC, non-small cell lung cancer; CCK-8, Cell Counting Kit-8; ANOVA, analysis of variance; LSD, least significant difference.

Journal: Oncology Reports

Article Title: Sirtuin 7 promotes non-small cell lung cancer progression by facilitating G1/S phase and epithelial-mesenchymal transition and activating AKT and ERK1/2 signaling

doi: 10.3892/or.2020.7672

Figure Lengend Snippet: SIRT7 promotes growth and G1 to S-phase transition of human NSCLC cells. (A) CCK-8 analysis of NSCLC cell proliferation/growth. *P<0.05, two-way repeated measures ANOVA with LSD post hoc multiple comparisons, n=6 per group. (B and C) Colony formation assay. (B) The representative images. (C) The relative clonogenic ability of A549-SIRT7 (A549-mock served as a control) and H292-shSIRT7 (H292-shcontrol served as a control) NSCLC cells. *P<0.05, Student t -test, n=6 per group. (D-F) Tumor subcutaneous xenograft mouse model. (D) Tumor volume. *P<0.05, two-way repeated measures ANOVA with LSD post hoc multiple comparisons, n=6 per group. (E) The xenograft tumor images. (F) Tumor weight. *P<0.05, Student's t -test, n=6 per group. (G and H) Cell cycle analysis by flow cytometry. (G) The representative images. (H) The percentage of each cell cycle phase. *P<0.05, Student's t -test, n=6 per group. SIRT7, sirtuin 7; NSCLC, non-small cell lung cancer; CCK-8, Cell Counting Kit-8; ANOVA, analysis of variance; LSD, least significant difference.

Article Snippet: The pGEM/SIRT7 cloning plasmid carrying human SIRT7 coding sequence (CDS) (BC017305) was supplied by Sino Biological, Inc. Plasmids including pLenti6.3/IRES/GFP lentiviral plasmid-expressing blasticidin S deaminase and green fluorescent protein (GFP) as well as pLP1, pLP2 and VSVG lentiviral packing plasmids were supplied by Novobio Scientific, Inc. Lentiviruses including control shRNA lentivirus (LV-shcontrol) and SIRT7 shRNA (h) lentivirus (LV-shSIRT7) containing puromycin resistance gene were supplied by Santa Cruz Biotechnology, Inc.

Techniques: Sublimation, CCK-8 Assay, Colony Assay, Control, Cell Cycle Assay, Flow Cytometry, Cell Counting

SIRT7 facilitates human NSCLC cell in vitro migration and invasion as well as in vivo distant lung metastasis. (A and B) Wound healing assay. (A) The representative images. (B) The relative migratory ability of A549-SIRT7 (A549-mock served as a control) and H292-shSIRT7 (H292-shcontrol served as a control) NSCLC cells. (C and D) Transwell migration assay. (C) The representative images. (D) The relative migratory ability of the aforementioned cells. (E and F) Transwell invasion assay. (E) The representative images. (F) The relative invasive ability of the aforementioned cells. (G) The representative H&E staining images of lung tissues. (H) The number of tumor metastatic nodules in lung tissues. *P<0.05, Student's t -test, n=6 per group. SIRT7, sirtuin 7; NSCLC, non-small cell lung cancer; H&E, hematoxylin and eosin.

Journal: Oncology Reports

Article Title: Sirtuin 7 promotes non-small cell lung cancer progression by facilitating G1/S phase and epithelial-mesenchymal transition and activating AKT and ERK1/2 signaling

doi: 10.3892/or.2020.7672

Figure Lengend Snippet: SIRT7 facilitates human NSCLC cell in vitro migration and invasion as well as in vivo distant lung metastasis. (A and B) Wound healing assay. (A) The representative images. (B) The relative migratory ability of A549-SIRT7 (A549-mock served as a control) and H292-shSIRT7 (H292-shcontrol served as a control) NSCLC cells. (C and D) Transwell migration assay. (C) The representative images. (D) The relative migratory ability of the aforementioned cells. (E and F) Transwell invasion assay. (E) The representative images. (F) The relative invasive ability of the aforementioned cells. (G) The representative H&E staining images of lung tissues. (H) The number of tumor metastatic nodules in lung tissues. *P<0.05, Student's t -test, n=6 per group. SIRT7, sirtuin 7; NSCLC, non-small cell lung cancer; H&E, hematoxylin and eosin.

Article Snippet: The pGEM/SIRT7 cloning plasmid carrying human SIRT7 coding sequence (CDS) (BC017305) was supplied by Sino Biological, Inc. Plasmids including pLenti6.3/IRES/GFP lentiviral plasmid-expressing blasticidin S deaminase and green fluorescent protein (GFP) as well as pLP1, pLP2 and VSVG lentiviral packing plasmids were supplied by Novobio Scientific, Inc. Lentiviruses including control shRNA lentivirus (LV-shcontrol) and SIRT7 shRNA (h) lentivirus (LV-shSIRT7) containing puromycin resistance gene were supplied by Santa Cruz Biotechnology, Inc.

Techniques: In Vitro, Migration, In Vivo, Wound Healing Assay, Control, Transwell Migration Assay, Transwell Invasion Assay, Staining

SIRT7 activates AKT/ERK1/2 signaling and regulates the expression of G1-phase checkpoint molecules for G1 to S transition as well as EMT molecules for EMT induction in NSCLC cells. (A and B) Western blot analysis of AKT/ERK1/2, G1-phase checkpoint and EMT molecules. (A) The representative western blot images. (B) The relative level of p-AKT (T308)/AKT, p-AKT (S473)/AKT and p-ERK1/2/ERK1/2 as well as p21, p27, cyclin D1, cyclin E1, CDK2, CDK4, E-cadherin, N-cadherin, vimentin, Snail and Slug in A549-SIRT7 (A549-mock served as a control) or H292-shSIRT7 (H292-shcontrol served as a control) NSCLC cells. *P<0.05, Student's t -test, n=6 per group. (C) IHC analysis of AKT/ERK1/2, G1-phase checkpoint and EMT molecules in xenograft tumor tissues. The representative IHC images are presented. SIRT7, sirtuin 7; EMT, epithelial-mesenchymal transition; NSCLC, non-small cell lung cancer; AKT, protein kinase; ERK1/2, extracellular signal-regulated kinase 1/2; CDK, cyclin-dependent kinase; IHC, immunohistochemistry.

Journal: Oncology Reports

Article Title: Sirtuin 7 promotes non-small cell lung cancer progression by facilitating G1/S phase and epithelial-mesenchymal transition and activating AKT and ERK1/2 signaling

doi: 10.3892/or.2020.7672

Figure Lengend Snippet: SIRT7 activates AKT/ERK1/2 signaling and regulates the expression of G1-phase checkpoint molecules for G1 to S transition as well as EMT molecules for EMT induction in NSCLC cells. (A and B) Western blot analysis of AKT/ERK1/2, G1-phase checkpoint and EMT molecules. (A) The representative western blot images. (B) The relative level of p-AKT (T308)/AKT, p-AKT (S473)/AKT and p-ERK1/2/ERK1/2 as well as p21, p27, cyclin D1, cyclin E1, CDK2, CDK4, E-cadherin, N-cadherin, vimentin, Snail and Slug in A549-SIRT7 (A549-mock served as a control) or H292-shSIRT7 (H292-shcontrol served as a control) NSCLC cells. *P<0.05, Student's t -test, n=6 per group. (C) IHC analysis of AKT/ERK1/2, G1-phase checkpoint and EMT molecules in xenograft tumor tissues. The representative IHC images are presented. SIRT7, sirtuin 7; EMT, epithelial-mesenchymal transition; NSCLC, non-small cell lung cancer; AKT, protein kinase; ERK1/2, extracellular signal-regulated kinase 1/2; CDK, cyclin-dependent kinase; IHC, immunohistochemistry.

Article Snippet: The pGEM/SIRT7 cloning plasmid carrying human SIRT7 coding sequence (CDS) (BC017305) was supplied by Sino Biological, Inc. Plasmids including pLenti6.3/IRES/GFP lentiviral plasmid-expressing blasticidin S deaminase and green fluorescent protein (GFP) as well as pLP1, pLP2 and VSVG lentiviral packing plasmids were supplied by Novobio Scientific, Inc. Lentiviruses including control shRNA lentivirus (LV-shcontrol) and SIRT7 shRNA (h) lentivirus (LV-shSIRT7) containing puromycin resistance gene were supplied by Santa Cruz Biotechnology, Inc.

Techniques: Expressing, Western Blot, Control, Immunohistochemistry

SIRT7 promotes NSCLC cell proliferation and EMT progression by activating AKT signaling. (A) CCK-8 assay after treatment with an AKT inhibitor (MK-2206). *P<0.05 compared with A549-SIRT7 or A549-SIRT7+DMSO, two-way repeated measures ANOVA with LSD post hoc multiple comparisons, n=6 per group. (B) Wound healing assay after treatment with the AKT inhibitor (MK-2206). *P<0.05 compared with A549-SIRT7 or A549-SIRT7+DMSO, one-way repeated measures ANOVA with LSD post hoc multiple comparisons, n=6 per group. (C) Transwell invasion assay after treatment with the AKT inhibitor. *P<0.05 compared with A549-SIRT7 or A549-SIRT7+DMSO, one-way repeated measures ANOVA with LSD post hoc multiple comparisons, n=6 per group. (D) Western blot analysis of EMT markers after treatment with the AKT inhibitor. The representative western blot images are presented. SIRT7, sirtuin 7; EMT, epithelial-mesenchymal transition; NSCLC, non-small cell lung cancer; EMT, epithelial-mesenchymal transition; AKT, protein kinase B; CCK-8, Cell Counting Kit-8; DMSO, dimethylsulfoxide; ANOVA, analysis of variance; LSD, least significant difference.

Journal: Oncology Reports

Article Title: Sirtuin 7 promotes non-small cell lung cancer progression by facilitating G1/S phase and epithelial-mesenchymal transition and activating AKT and ERK1/2 signaling

doi: 10.3892/or.2020.7672

Figure Lengend Snippet: SIRT7 promotes NSCLC cell proliferation and EMT progression by activating AKT signaling. (A) CCK-8 assay after treatment with an AKT inhibitor (MK-2206). *P<0.05 compared with A549-SIRT7 or A549-SIRT7+DMSO, two-way repeated measures ANOVA with LSD post hoc multiple comparisons, n=6 per group. (B) Wound healing assay after treatment with the AKT inhibitor (MK-2206). *P<0.05 compared with A549-SIRT7 or A549-SIRT7+DMSO, one-way repeated measures ANOVA with LSD post hoc multiple comparisons, n=6 per group. (C) Transwell invasion assay after treatment with the AKT inhibitor. *P<0.05 compared with A549-SIRT7 or A549-SIRT7+DMSO, one-way repeated measures ANOVA with LSD post hoc multiple comparisons, n=6 per group. (D) Western blot analysis of EMT markers after treatment with the AKT inhibitor. The representative western blot images are presented. SIRT7, sirtuin 7; EMT, epithelial-mesenchymal transition; NSCLC, non-small cell lung cancer; EMT, epithelial-mesenchymal transition; AKT, protein kinase B; CCK-8, Cell Counting Kit-8; DMSO, dimethylsulfoxide; ANOVA, analysis of variance; LSD, least significant difference.

Article Snippet: The pGEM/SIRT7 cloning plasmid carrying human SIRT7 coding sequence (CDS) (BC017305) was supplied by Sino Biological, Inc. Plasmids including pLenti6.3/IRES/GFP lentiviral plasmid-expressing blasticidin S deaminase and green fluorescent protein (GFP) as well as pLP1, pLP2 and VSVG lentiviral packing plasmids were supplied by Novobio Scientific, Inc. Lentiviruses including control shRNA lentivirus (LV-shcontrol) and SIRT7 shRNA (h) lentivirus (LV-shSIRT7) containing puromycin resistance gene were supplied by Santa Cruz Biotechnology, Inc.

Techniques: CCK-8 Assay, Wound Healing Assay, Transwell Invasion Assay, Western Blot, Cell Counting